Two recent studies published in Nature focused on the clinical efficacy of the menin inhibitor revumenib (SNDX-5613) in KMT2A (histone-lysine N-methyltransferase 2A)-rearranged or NPM1 (Nucleophosmin1)-mutant acute myeloid leukemia.1,2 These studies indicate that menin inhibition and its acquired resistance to long-term exposure to revuminib are key points for future treatment, emphasizing the role of menin as a challenging and promising target for the current treatment of leukemia. This evidence concerns the gene NPM1 and leukemia.